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Agreement was moderate between data-based and 
opinion-based assessments of biases affecting 
randomised trials within meta-analyses 
ABSTRACT 
Background: Randomised trials included in meta-analyses are often affected by bias caused by 
methodological flaws or limitations, but the degree of bias is unknown. Two proposed methods adjust 
trial results for bias using: (1) empirical evidence from published meta-epidemiological studies; or (2) 
expert opinion. 
Methods: We investigated agreement between data-based and opinion-based approaches to assessing 
bias in each of four domains: sequence generation, allocation concealment, blinding and incomplete 
outcome data. From each sampled meta-analysis, a pair of trials with the highest and lowest empirical 
model-based bias estimates was selected. Independent assessors were asked which trial within each 
pair was judged more biased on the basis of detailed trial design summaries. 
Results: Assessors judged trials to be equally biased in 68% of pairs evaluated. When assessors 
judged one trial as more biased, the proportion of judgements agreeing with the model-based ranking 
was highest for allocation concealment (79%) and blinding (79%) and lower for sequence generation 
(59%) and incomplete outcome data (56%). 
Conclusions: Most trial pairs found to be discrepant empirically were judged to be equally biased by 
assessors. We found moderate agreement between opinion and data-based evidence in pairs where 
assessors ranked one trial as more biased. 
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What is new? 
Key findings 
• We found moderate agreement between opinion and data-based evidence in the rankings of pairs of 
randomised trials by bias severity, in pairs where assessors ranked one trial as more biased.  
• Most trial pairs found to be discrepant empirically under a bias model fitted to meta-epidemiological 
data were judged to be equally biased by assessors. 
What this adds to what was known 
• Methods for bias adjustment in meta-analysis have been proposed by a number of authors and are 
usually informed by empirical evidence or elicited expert opinion on bias. 
• The extent to which assessors’ opinions on bias are similar to empirical estimates informed by meta-
epidemiological research has not previously been evaluated. 
• Bias adjustment can be informed by a combination of empirical evidence and opinion, with the aim 
of reducing uncertainty by using knowledge of the specific studies included in a meta-analysis. 
What is the implication and what should change now 
• Our finding that the majority of trial pairs were ranked as equally biased suggests that incorporating 






A meta-analysis of the results from relevant randomised trials is often regarded as the best evidence 
evaluating the effectiveness of a healthcare intervention (1). Meta-analysis results summarise the 
findings from multiple studies and are more precise and usually more influential than results from a 
single trial. Their findings inform public health policy decisions made by organisations such as the 
National Institute for Health and Care Excellence (NICE), as well as healthcare decisions made by 
individual patients, doctors and institutions. Randomised trials vary in methodological quality, and 
flaws in trial conduct can lead to biased estimation of the intervention effect (2). If a meta-analysis 
makes no allowance for  methodological flaws, there is a danger that the results could be biased and 
more precise than they should be (3), which can lead to inappropriate healthcare decisions. 
Randomised trials should employ rigorous methods that minimise the risk of bias and preserve 
comparability of the intervention groups. For example, concealment of randomised allocation ensures 
that the order of assignments to intervention groups cannot be predicted in advance and thereby 
removes the influence of patient characteristics on the probability of assignment to a group. Blinding 
of participants and caregivers to randomised allocation prevents differences in patient management 
between groups and blinding of outcome assessors (including participants when outcomes are 
reported by them) prevents knowledge of allocation influencing outcome measurement. Inadequacies 
in allocation concealment and blinding have been found to be associated with exaggeration of 
intervention effects (4-8). Meta-analyses often include trials that vary in methodological adequacy 
with respect to these characteristics and others. 
Assessing the risk of bias in included studies is a mandatory step in a systematic review (9, 10) but 
there is no established method for combining bias assessments with a meta-analysis to guide 
interpretation of the effect of an intervention. The majority of systematic reviews do not incorporate 
bias assessments into the statistical analysis (11). In those which do incorporate bias assessments, the 
most common approach is to perform a sensitivity analysis excluding high risk studies, following a 
primary analysis including all evidence. This is problematic because it requires researchers to 




many meta-analyses, a criterion to dichotomise trials as good or bad is not easily chosen and, if few 
trials remain eligible for inclusion, precision could be greatly reduced. For example, 43% of trials 
were judged to be at high risk of bias for at least one domain of the Cochrane Risk of Bias tool (12), 
so exclusion on this basis could almost halve the number of trials included. Under this approach to 
addressing biases, discarded trials are regarded as providing no useful information at all, while 
included trials are implicitly assumed to be unaffected by within-trial biases. Most meta-analyses 
include trials which lie somewhere between these two extremes. Although sensitivity analyses based 
on risk of bias are often reported, decision making will usually be based on a single summary result, 
and it would therefore be desirable for the primary meta-analysis to incorporate adjustment for within-
trial biases. Adjusting a meta-analysis for biases that are present in included trials is often considered 
controversial. However, the conventional approach of making no adjustment to the results even when 
potential causes of bias are present in a trial is equivalent to assigning an extremely strong opinion to 
the assumption that the bias is equal to zero. 
Methods for bias adjustment in meta-analysis have been proposed by a number of authors, allowing 
the influence of evidence from less rigorous trials to be reduced in the combined analysis (3, 13-17). 
Although the potential causes of bias are often known, the impact of bias affecting each trial is 
unknown. Distributions describing the expected level of within-trial bias and the uncertainty about the 
bias are constructed from external evidence, which is typically in the form of expert opinion or 
relevant empirical data. Empirical evidence on biases affecting randomised trials is available from 
meta-epidemiological studies which analyse large numbers of meta-analyses to examine the 
association between trial design characteristics and trial results (18). Meta-epidemiological research 
has provided evidence on the biases associated with flaws in sequence generation, allocation 
concealment, blinding and incomplete outcome data (4-6, 19-21). Welton et al. (17) proposed a 
method which uses generic empirical evidence on the magnitude of biases, obtained from meta-
epidemiological studies based on collections of meta-analyses. Turner et al. (16) proposed a method 




of the trials in the meta-analysis. The extent to which assessors’ opinions on bias are similar to 
empirical estimates informed by meta-epidemiological research has not previously been evaluated. 
In some instances, it would be desirable for bias adjustment in meta-analysis to be informed by a 
combination of empirical evidence on bias and opinion. For example, available meta-epidemiological 
evidence may be considered only partially relevant to a specific meta-analysis because of a difference 
in population or intervention settings, and expert opinion could be used to adjust the data-based 
distribution for bias to the target setting. If relying on meta-epidemiological evidence alone, the 
predicted distribution for within-trial bias is often very imprecise, because it allows for variability in 
bias across the collection of meta-analyses. By using opinion informed by knowledge of the studies 
included in a meta-analysis, it is likely that this uncertainty can be reduced. Using a combination of 
data-based evidence and opinion for the reasons described above would be considered more valid if 
these approaches were known to produce similar estimates for bias. 
In this research, we obtain opinions on the bias associated with four domains, using meta-analyses 
sampled from a meta-epidemiological study.  Our aims were to examine agreement among experts 
and subsequently to explore agreement between empirical data-based and opinion-based approaches 
to assessing bias. 
METHODS 
Outline of our approach 
The  approach to adjusting for biases based on empirical evidence involves fitting a hierarchical 
model to the data from trials included in each of a collection of meta-analyses (17). For our 
investigations we used data from the Risk of Bias in Evidence Synthesis (ROBES) study (6). Within 
each meta-analysis extracted from the ROBES database, we selected the two trials with the highest 
and lowest model-based bias estimates, and then elicited opinion on which trial was judged to be more 
biased. We examined agreement between model-based and opinion-based estimates of bias within 





The ROBES database consists of meta-analyses extracted from the April 2011 issue of the Cochrane 
Database of Systematic Reviews, in which Cochrane review authors had implemented the ‘risk of 
bias’ tool to assess potential biases in included trials (22). The ROBES study (6) included 228 meta-
analyses in total, from Cochrane reviews that reported information on all five recommended risk of 
bias domains: sequence generation, allocation concealment, blinding, incomplete outcome data and 
selective outcome reporting. Review authors had recorded whether there was a low, high or unclear 
risk of bias in each bias domain, together with comments or quotes from the trial publication to justify 
each judgement. Meta-analyses were excluded if they included fewer than five trials or if a summary 
estimate was not reported in the review (for example, because pooling was considered inappropriate). 
One or more binary outcome meta-analyses (with sets of included trials that were unique to each 
meta-analysis) from each eligible review were included in the ROBES database; primary outcomes 
were chosen where possible (6). 
Selection of pairs of trials within meta-analyses 
For each meta-analysis, we selected a pair of trials with the highest and lowest model-based bias 
estimates, representing the least and the most biased trials among those included in the meta-analysis, 
for each of four bias domains: allocation concealment; sequence generation; blinding and incomplete 
outcome data. These pairs were selected in order to present them to expert assessors, asking them 
which trial of each pair they judged to be at the greatest risk of bias in each domain examined. The 
process of selecting pairs of trials is described in detail below. 
For each bias domain in turn, we first sampled 30 meta-analyses from the ROBES study. Meta-
analyses included in the ROBES study were sampled from the Cochrane Database of Systematic 
Reviews in April 2011. Meta-analyses were sampled from the set of meta-analyses including at least 
one trial judged to be at low risk of bias and at least two trials judged to be at high or unclear risk of 
bias. A trial at low risk was needed as a comparator, to enable bias estimates to be obtained for trials 
with high or unclear risk judgements; at least two of the latter were required in order that the two with 
highest and lowest bias estimates could be selected. For example, when sampling meta-analyses to 




least one trial assessed by review authors to have adequate allocation concealment and at least two 
trials assessed to have inadequate or unclear allocation concealment. To ensure that different outcome 
types were represented, each set of 30 meta-analyses comprised randomly selected samples of 15 
eligible meta-analyses with outcomes judged to be objective or semi-objective (“objectively 
ascertained but potentially influenced by judgement”) in the ROBES study and 15 eligible meta-
analyses with outcomes judged to be subjective or of mixed types within the meta-analysis (6). 
Choice of sample size of 30 meta-analyses per bias domain is justified in the Appendix. 
For each bias domain in turn, we fitted the bias model proposed by Welton et al to all meta-analyses 
in the ROBES database and obtained estimates (together with uncertainty) for the trial-specific biases 
within the 30 sampled meta-analyses. The binary outcome data miar , mian  (representing number of 
events and total number of subjects) from each trial arm a of trial i within meta-analysis m were 
assumed to have a binomial likelihood, ( )~ ,mia mia miar Bin p n . The following hierarchical bias model 
includes effects of trial-specific biases mi  associated with a known trial characteristic miZ , and 
allows for within-meta-analysis bias variation 
2  and between-meta-analysis bias variation 2  (17). 
Treatment effects mi  are assumed random across trials within meta-analyses, with separate between-
trial heterogeneity variances 
2
m . The values of mi  and 
2
m  were assumed to be unrelated across 
meta-analyses. 
   

























   (1) 
Posterior mean values of the mi  were used as bias estimates, and viewed as model-based 
assessments for the extent of bias in particular trials. These are shrinkage estimates of bias, based on 




Next, for each bias domain in turn and within each sampled meta-analysis, we selected the pair of 
trials with the highest and lowest bias estimates, among the trials with a judgement of high or unclear 
risk of bias. Selected pairs of trials from each of the sampled meta-analyses formed our study data set 
in which empirical data-based and opinion-based approaches to assessing bias were compared.  
Elicitation of opinion on bias 
Every trial in each pair was summarised by a description of the trial participants, interventions, 
outcomes and methods (together with additional notes, if available), extracted from the study 
characteristics tables reported by Cochrane reviewers. Trial sample sizes were added to each trial 
design summary, but no treatment effect estimates were provided. Support text for risk of bias 
judgements (without the actual judgements) was extracted from the Cochrane risk of bias tables for 
each trial and included in the summary information and checked against the original trial reports by 
the research team. If no support text was available in the risk of bias table or if it was incomplete, 
vague or not directly relevant to the given bias domain, it was extracted from trial reports by the 
research team. 
We recruited six assessors (AH, DC, RM, BCR, HW, IB) with expertise in clinical research 
methodology and evidence-based medicine, by personal invitation. For each trial pair, assessors were 
given information packs (see example in Appendix) and asked to complete them independently. In 
total, each trial pair was assessed three times, by three out of six assessors. Trials within the pairs 
were labelled “trial A” and “trial B” at random. For each of four bias domains (sequence generation, 
allocation concealment, blinding, incomplete outcome data), the assessors were asked to choose 
between the following three judgements: “trial A is more biased”, “trial B is more biased”, or “trial A 
and trial B are equally biased”. We note that assessors were asked to make judgements for all four 
bias domains, without knowledge of the bias domain for which the trial pair had been selected. In 
addition, assessors were asked to choose between the same three judgements with respect to overall 
risk of bias. Alongside each judgement, assessors were asked to provide a rating from 1 to 5 for their 
confidence in that judgement, where 1 represents “not at all confident” and 5 represents “very 




to discuss their judgements with other assessors; several assessors required more time and completed 
the work later on. 
Data analysis 
We examined agreement in the trial pair rankings (ordering of trials A and B with respect to extent of 
bias) among the bias assessors, using unweighted kappa statistics and 95% confidence intervals. 
Analyses were performed for each bias domain separately and then for all bias domains combined, 
using rankings from all trial pairs in the study data set. 
We assessed agreement between the trial pair rankings produced by assessors and the ranking based 
on estimated biases from the bias model. We reported the proportion of trial pairs in which assessors 
chose one trial as more biased (rather than saying they were equally biased). Of the judgements in 
which one trial was believed to be more biased than the other, we calculated the proportion in which 
assessor opinion agreed with the model-based ranking of the trials. Analyses were performed for each 
bias domain separately, using the rankings from the subset of 30 meta-analyses sampled for that bias 
domain.  
Next, we conducted exploratory multinomial logistic regression analyses to examine the association 
between assessor opinions and model-based differences in bias estimates between the trials in each 
pair. We used regression to explore whether agreement between assessor ranking and model-based 
ranking was associated with the magnitude of the difference in estimated biases for each trial pair. For 
each combination of trial pair (i) and assessor (j), there are three possible outcomes: disagreement 
between the assessor and model-based rankings, agreement between the assessor and model-based 
rankings, or assessors ranking trials as equally biased. Disagreement between the assessor and model-
based ranking was treated as the baseline category (k=0) for the response variable, and a multinomial 
logistic regression model was created to estimate the odds ratio for each of the two alternative 
categories: assessors ranking trials as equally biased  (k=1), and assessors agreeing with the model-
based ranking (k=2). As a single covariate in the model we included the magnitude of difference in 




( ) k i ik jklogit = α + x +u +  ijk k ,     (2) 
where ijk  represents the probability of outcome category k for assessor  j in trial pair i, and ix  is the 
model-based difference in bias estimates (calculated as the difference between the most extreme and 
least extreme bias values). To allow for similarity in judgements on the same trial pair (or 
equivalently, variation between trial pairs), we included a random intercept iu  for each of the 30 trial 
pairs. We also included a fixed effect j  for each of the six different assessors. We focus on the 
regression coefficient 2  of the model-based difference in bias estimates. A positive value for this 
coefficient indicates that, on average, assessor agreement with model-based rankings is associated 
with the magnitude of the estimated difference in bias from the model. 
All regression models were fitted using MCMC methods within WinBUGS (23) (see Appendix).     
RESULTS 
Descriptive analyses 
Our data set consisted of 101 trial pairs in total because there was some overlap between the sets of 30 
meta-analyses sampled for each of the four bias domains. Table 1 summarises the types of 
interventions and outcomes evaluated in the sampled meta-analyses. The majority (64%) of sampled 
meta-analyses corresponded to pharmacological vs. placebo/control comparisons, while 25% were 
non-pharmacological vs. control comparisons, and the remainder represented comparisons of two 
active treatments. Objective outcomes were evaluated in 36% of sampled meta-analyses overall, 16% 
evaluated semi-objective (“objectively ascertained but potentially influenced by judgement”) 
outcomes and 46% evaluated subjective outcomes. The median number of trials included in the meta-
analyses was 13 (inter-quartile range 9 to 24). Meta-analysis characteristics were fairly similar across 
the meta-analysis samples selected for each bias domain (Table 1). 
Table 2 shows the frequencies of risk of bias profiles (combinations of risk of bias judgements for the 
four bias domains, reported by Cochrane authors) among the trials selected as having the lowest or 




unclear risk of bias for three or four bias domains and no trials had low risk of bias judgements for all 
domains. Differences within trial pairs are summarised in Table 3. Risk of bias judgements differ 
within pairs for only one bias domain or no bias domains in 59/101 trial pairs, and differ for all four 
bias domains in only 4/101 pairs. 
Table 4 describes the extent of agreement among the bias assessors when judging which trial of each 
pair they believed to be more biased, showing the estimated kappa statistics in the rankings of the 
three assessors. There was fair to moderate agreement among the rankings. For sequence generation, 
the percentage of pairs in which all three assessments agreed was 50% and the kappa statistic was 
0.43 (95% CI: 0.37 to 0.50). For allocation concealment, the percentage in which all three assessors 
were in agreement was 56% and the kappa statistic was 0.46 (95% CI: 0.40 to 0.52). There was 
moderate agreement among rankings for blinding: the percentage agreement across all three assessors 
was 60% and kappa was estimated as 0.45 (95% CI: 0.39 to 0.51). There was less agreement among 
assessors for incomplete outcome data: the percentage in which all three assessors agreed was 31% 
and the kappa statistic was 0.21 (95% CI: 0.14 to 0.27). For overall risk of bias, the percentage of trial 
pairs in which all three assessors agreed was 32% and the kappa statistic was 0.26 (95% CI: 0.19 to 
0.32). 
The assessors specified a confidence level of 1 (not at all confident) to 5 (very confident) about their 
opinion. We summarize the confidence levels in Figure 1. Assessor confidence levels were 
comparable for sequence generation, allocation concealment and blinding. For each of these bias 
domains, the median confidence level across all trial pairs and all assessors was 3 (inter-quartile range 
(IQR): 2 to 4). Confidence levels tended to be lower for incomplete outcome data and for overall bias 
(median 2, IQR: 1 to 3 for each). Confidence levels were no higher when examined only in the bias 
domain for which the trial pair had been selected. 
For each bias domain, 30 trial pairs were ranked by each of three assessors, resulting in 90 assessor 
opinions. For sequence generation, 36 (40%) of the 90 assessor opinions ranked one trial as more 
biased than the other (Table 2). For allocation concealment, blinding and incomplete outcome data 




reports the proportion of assessor opinions that agreed with the model-based ranking of trial pairs. 
Among the assessor opinions which judged one trial as more biased (rather than trials equally biased), 
the proportion that agreed with the ranking based on the bias model was high for allocation 
concealment (79%) and blinding (79%). For sequence generation and assessment of incomplete 
outcome data, agreement was lower at 59% and 56% respectively (i.e. not much better than chance). 
Regression analyses 
In the exploratory multinomial logistic regression analyses, we focus on the regression coefficient 2  
of the model-based difference in fitted bias (Table 6). Although this was estimated as positive for 
allocation concealment and incomplete outcome data, the 95% credible intervals were very wide and 
contained the null value, representing no association between the magnitude of difference in model-
based bias estimates and agreement between assessor and model-based rankings. For sequence 
generation and blinding, the regression coefficient was estimated as negative, again with very wide 
95% credible intervals containing the null value. Similarly, we cannot conclude whether smaller 
differences in model-based bias estimates were associated with assessors ranking trials as equally 
biased. There is insufficient information in the data for us to be able to draw any conclusions from the 
results (Table 6): all intervals for model parameters were wide and close to the ranges of the assigned 
prior distributions. 
DISCUSSION 
Agreement between opinion-based and model-based rankings of bias magnitude was high for 
sequence generation and allocation concealment and moderate for blinding and incomplete outcome 
data, among trial pairs in which assessors ranked one trial as more biased. However, in the majority of 
trial pairs, assessors ranked trials as equally biased, although the two trials had been selected on the 
basis of having high and low bias estimates (within a given meta-analysis) under the bias model fitted. 
In these trial pairs, detailed trial descriptions did not lead assessors to judge the bias as higher in one 
trial than another. There was fair to moderate agreement in rankings across bias assessors. In 




associations between the magnitude of difference in model-based bias estimates and assessors 
agreeing with model-based rankings or assessors ranking trials as equally biased. 
Published methods for bias adjustment in meta-analysis suggest making use of either empirical data-
based evidence on biases or opinion on biases (3, 13, 15-17), but no previous comparison has been 
made between data-based distributions and assessors’ opinions on bias. Access to a large collection of 
meta-analyses for which review authors have reported risk of bias judgements and supporting 
information has enabled us to carry out a comparative study. We note that the empirical data-based 
distributions for bias were themselves informed indirectly by opinion, since they were derived from a 
hierarchical model fitted to trial data within meta-analyses, in which judgement about each trial’s risk 
of bias was used as a covariate. The model-based rankings rely on the appropriateness of the assumed 
model for the data and also on the risk of bias judgements reported by Cochrane reviewers. Reviewers 
follow risk of bias protocols that aim to maximise reproducibility. It would not be possible to adjust a 
meta-analysis for trial-specific biases without incorporating some form of subjective judgement.  
Formal validation methods are not available for bias assessments, since the true extent of bias in a 
given trial is unknown, but agreement between independent bias assessments would increase our 
confidence in them. 
Since the actual magnitude of bias affecting the trial pairs selected from the sampled meta-analyses 
remains unknown, it is not possible to evaluate whether the data-based or opinion-based rankings are 
closer to the truth. Assessors indicated that their confidence in their own opinions on the rankings of 
trials within pairs was moderate or low. In our study, assessors were asked to carry out a large number 
of rankings during one day (though several assessors required more time and completed the work later 
on); the high workload may have affected their performance. When assessors are asked to provide 
opinions on biases affecting studies in a single meta-analysis, the number of studies assessed would 
typically be much smaller. We observed less agreement among assessors for incomplete outcome data 
than for the other bias domains. This may be related to the greater complexity of the bias in this 
domain, which depends on several factors, including the amount and distribution of missing data 




participants, and how the problem has been addressed in reported analyses (24). We aimed to assess 
agreement among assessors pragmatically, so we did not attempt to increase inter-observer agreement 
before carrying out the elicitation exercise. 
In this work, opinions about biases were based on summary information about trials, informed 
primarily by the study characteristics and risk of bias tables reported by Cochrane reviewers and 
supplemented by additional information extracted from the trial reports by the research team. 
Assessors reported some difficulties in assessing bias on the basis of summary information and 
commented that for certain trials they would have liked access to the original trial publications. When 
eliciting opinions about within-trial biases, it might therefore be preferable to provide full 
publications, as Turner et al. did in their opinion-based method for bias adjustment (16), although this 
introduces some risk that assessments of bias are influenced by knowledge of the trial results unless 
all results are removed. Using all available sources of information (e.g. publication, statistical analysis 
plan, protocol, trial registration records etc.) is generally encouraged for assessing risk of bias in 
RCTs included in systematic reviews (25), to improve confidence in assessment. We were surprised 
that the majority of trial pairs were ranked as equally biased and we suspect that the lack of detailed 
trial information contributed to this. We expect that differentiation between trials was reduced also by 
requesting categorical judgements for each trial pair rather than continuous judgements of bias (using 
a visual analogue scale, for example) for each individual trial. Trials judged to be at high or unclear 
risk of bias were grouped together in the hierarchical model used to estimate bias. Research has 
suggested that many trials judged to be at unclear risk of bias for sequence generation and allocation 
concealment could be reclassified as low risk if information outside the trial publications was 
obtained (26). Misclassification of risk of bias judgements may have reduced or increased the 
differences within some of the selected trial pairs. 
Risk of bias judgements are increasingly published for trials included in Cochrane reviews. It is 
desirable to incorporate these judgements about suspected biases into the statistical analyses 
performed and interpretation of the review findings (10, 11). The Cochrane database could in time 




judgements for different domains. In a separate paper, we have explored methods for quantifying bias 
by using empirical distributions for the bias affecting trials with a specific set of risk of bias 
judgements, in combination with expert opinion (27). However, our finding in this paper that the 
majority of trial pairs were ranked as equally biased suggests that incorporating opinion on bias may 
not reduce uncertainty much, compared with using empirical distributions alone. 
We found moderate agreement between opinion and data-based evidence in the rankings of trial pairs 
by bias severity, in pairs where assessors ranked one trial as more biased. This finding provides some 
support for approaches combining data-based evidence with opinion on bias. However, trials were 
ranked as equally biased in the majority of trial pairs, indicating that trial summaries did not provide 
sufficient information to reach a ranking judgement. 
Acknowledgements 
This project was funded by the UK Medical Research Council (MRC) grant (MR/K014587/1). RMT 
and KMR were supported by the MRC programme grant (U105260558).  RMT was also supported by 
the MRC grant MC_UU_12023/21 and KMR also by the MRC grant MC_UU_00002/5. HEJ was 
supported by a MRC career development award in biostatistics (MR/M014533/1). JPTH is an NIHR 
Senior Investigator (NF-SI-0617-10145), a member of the MRC Integrative Epidemiology Unit at the 
University of Bristol, and is supported by the NIHR Applied Research Collaboration  West (ARC 
West) at University Hospitals Bristol NHS Foundation Trust and the NIHR Bristol Biomedical 
Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. 
JS was supported by the MRC fellowship (G0701659/1) and the National Institute for Health 
Research (NIHR) ARC West  at University Hospitals Bristol NHS Foundation Trust.  The views 
expressed are those of the authors and not necessarily those of the MRC, the National Health Service, 
the NIHR or the Department of Health and Social Care. 
Declaration of interests 
Isabelle Boutron is co-convenor of the Cochrane Bias Methods Group. 
References 
1. Egger M, Davey Smith G, Altman DG. Systematic reviews in health care: meta-analysis in 
context. London: BMJ Books; 2001. 
2. Gluud LL. Bias in clinical intervention research. American Journal of Epidemiology. 
2006;163:493-501. 
3. Greenland S. Multiple-bias modelling for analysis of observational data (with discussion). 




4. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of 
methodological quality associated with estimates of treatment effects in controlled trials. Journal 
American Medical Association. 1995;273:408-12. 
5. Savovic J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, et al. Influence of reported study 
design characteristics on intervention effect estimates from randomised controlled trials: combined 
analysis of meta-epidemiological studies. Annals of Internal Medicine. 2012;157:429-38. 
6. Savovic J, Turner RM, Mawdsley D, Jones HE, Beynon R, Higgins JPT, et al. Association 
Between Risk-of-Bias Assessments and Results of Randomised Trials in Cochrane Reviews: The 
ROBES Meta-Epidemiologic Study. Am J Epidemiol. 2018;187(5):1113-22. 
7. Hrobjartsson A, Emanuelsson F, Skou Thomsen AS, Hilden J, Brorson S. Bias due to lack of 
patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and 
nonblind sub-studies. Int J Epidemiol. 2014;43(4):1272-83. 
8. Hrobjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer 
bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded 
and non-blinded outcome assessors. BMJ. 2012;344:e1119. 
9. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal 
tool for systematic reviews that include randomised or non-randomised studies of healthcare 
interventions, or both. BMJ. 2017;358:j4008. 
10. Higgins JPT, Lasserson T, Chandler J, Tovey D, Churchill R. Methodological Expectations of 
Cochrane Intervention Reviews. Version 1.06 ed. London: Cochrane; 2018. 
11. Hopewell S, Boutron I, Altman DG, Ravaud P. Incorporation of assessments of risk of bias of 
primary studies in systematic reviews of randomised trials: a cross-sectional study. BMJ Open. 
2013;3(8):e003342. 
12. Yordanov Y, Dechartres A, Porcher R, Boutron I, Altman DG, Ravaud P. Avoidable waste of 
research related to inadequate methods in clinical trials. BMJ. 2015;350:h809. 
13. Eddy DM, Hasselblad V, Schachter R. Meta-analysis by the Confidence Profile Method: The 
Statistical Synthesis of Evidence. San Diego, CA: Academic Press; 1992. 
14. Spiegelhalter DJ, Best NG. Bayesian approaches to multiple sources of evidence and 
uncertainty in complex cost-effectiveness modelling. Statistics in Medicine. 2003;22:3687-709. 
15. Wolpert RL, Mengersen KL. Adjusted likelihoods for synthesizing empirical evidence from 
studies that differ in quality and design: effects of environmental tobacco smoke. Statistical Science. 
2004;19:450-71. 
16. Turner RM, Spiegelhalter DJ, Smith GCS, Thompson SG. Bias modelling in evidence synthesis. 
Journal of the Royal Statistical Society, Series A. 2009;172:21-47. 
17. Welton NJ, Ades AE, Carlin JB, Altman DG, Sterne JAC. Models for potentially biased 
evidence in meta-analysis using empirically based priors. Journal of the Royal Statistical Society, 
Series A. 2009;172(1):119-36. 
18. Naylor CD. Meta-analysis and the meta-epidemiology of clinical research. BMJ. 
1997;315(7109):617-9. 
19. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of 
randomised trials affect estimates of intervention efficacy reported in meta-analyses? The Lancet. 
1998;352:609-13. 
20. Balk EM, Bonis PAL, Moskowitz H, Schmid CH, Ioannidis JPA, Wang C, et al. Correlation of 
quality measures with estimates of treatment effect in meta-analyses of randomised controlled 
trials. Journal American Medical Association. 2002;287:2973-82. 
21. Savovic J, Jones HE, Altman D, Harris R, Juni P, Pildal J, et al. Influence of reported study 
design characteristics on intervention effect estimates from randomised controlled trials: combined 
analysis of meta-epidemiological studies. Health Technology Assessment. 2012;16:1-82. 
22. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S, 





23. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: 
concepts, structure, and extensibility. Statistics and Computing. 2000;10(4):325-37. 
24. Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane 
Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. 
25. A revised tool to assess risk of bias in randomised trials (RoB 2)  [Available from: 
https://www.riskofbias.info/welcome/rob-2-0-tool. 
26. Vale CL, Tierney JF, Burdett S. Can trial quality be reliably assessed from published reports of 
cancer trials: evaluation of risk of bias assessments in systematic reviews. BMJ. 2013;346:f1798. 
27. Rhodes KM, Savovic J, Elbers R, Jones HE, Higgins JPT, Sterne JAC, et al. Adjusting trial results 
for biases in meta-analysis: combining data-based evidence on bias with detailed trial assessment. 





Table 1   Characteristics of meta-analyses sampled from the ROBES data set, for each bias domain and overall. 
















Type of intervention comparison      
Pharmacological vs. Placebo/control 17 (57%) 21 (70%) 19 (63%) 20 (67%) 65 (64%) 
Pharmacological vs. Pharmacological 5 (17%) 1 (3%) 1 (3%) 2 (7%) 8 (8%) 
Non-pharmacological vs. Placebo/control 8 (27%) 7 (23%) 8 (27%) 7 (23%) 25 (25%) 
Non-pharmacological vs. Non-pharmacological 0 (0%) 1 (3%) 2 (7%) 1 (3%) 3 (3%) 
Type of outcome measure      
Objective 11 (37%) 11 (37%) 10 (33%) 11 (37%) 36 (36%) 
Semi-objective 5 (17%) 4 (13%) 5 (17%) 3 (10%) 16 (16%) 
Subjective 13 (43%) 14 (47%) 14 (47%) 15 (50%) 46 (46%) 
Mixed types within the meta-analysis 1 (3%) 1 (3%) 1 (3%) 1 (3%) 3 (3%) 
Number of trials: median (interquartile 
range) 
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   11 (5%) 
 
 
   34 (17%) 
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   7 (3%) 
 
 
   5 (2%) 
 
 
   54 (27%) 
SG: sequence generation; AC: allocation concealment; B: blinding; IOD: incomplete outcome data 
  
   





















High/Unclear risk of bias 




Table 3   Differences in risk of bias profiles (from Cochrane reviews) within trial pairs 
 Frequency (%) 
(n=101) 
High/unclear/low judgements match for all bias domains 
 
23 (23%) 
Difference in judgements for one bias domain 
 
36 (36%) 
Differences in judgements for two bias domains 
 
27 (27%) 
Differences in judgements for three bias domains 
 
11 (11%) 





Table 4   Kappa statistics with 95% confidence intervals for assessing agreement in rankings among 
the three bias assessors. 
 










All 101 0.43 (0.37 to 0.50) Moderate agreement 50/101 (50%) 
Allocation 
concealment 
All 101 0.46 (0.40 to 0.52) Moderate agreement 57/101 (56%) 
Blinding 1001 0.45 (0.39 to 0.51) Moderate agreement 60/100 (60%) 
Incomplete 
outcome data  
991 0.21 (0.14 to 0.27) Fair agreement 31/99 (31%) 
Overall  971 0.26 (0.19 to 0.32) Fair agreement 31/97 (32%) 






Table 5   Frequency of assessor opinions ranking one trial as more biased (rather than choosing trials 
equally biased).  Of those that chose one trial as more biased, we report the proportion that agreed 




How often did 
the assessors 
choose one 





Of those that 






Sequence generation 36/90 (40%) 23/36 (59%) 
Allocation concealment 14/90 (16%) 11/14 (79%) 
Blinding 24/90 (27%) 19/24 (79%) 






1 A positive value for 
2  indicates that, on average, greater differences in estimated bias within trial pairs are associated with assessor rankings agreeing with the model-based rankings. 
2 A positive value for 
1  indicates that, on average, greater differences in estimated bias within trial pairs are associated with assessors ranking trials as equally biased.  
 
Table 6   Results from the exploratory multinomial regression to examine the association between assessor opinion and model-based difference in bias 
estimates: central parameter estimates (95% credible intervals).   
 
 

































Model-based difference in bias estimates1 ( )2  
 









Between-trial-pair standard deviation 




-0.77 (-2.95 to 1.06) 
N/A 
-0.52 (-3.88 to 2.80) 
0.27 (-2.14 to 2.61) 
1.32 (-1.66 to 4.50) 
1.59 (-0.93 to 4.34) 
 
 
3.31 (1.43 to 4.88) 
 




-1.21 (-4.67 to 1.79) 
-2.50 (-7.61 to 2.08) 
1.24 (-1.08 to 3.84) 
-0.35 (-4.39 to 3.52) 
-0.86 (-4.29 to 2.18) 
1.05 (-2.22 to 4.39) 
 
 
2.43 (0.06 to 4.70) 




0.08 (-4.07 to 4.11) 
1.98 (-0.04 to 4.38) 
-1.20 (-4.66 to 1.95) 
0.46 (-1.59 to 2.40) 
-1.76 (-6.94 to 2.64) 
0.50 (-2.82 to 3.93) 
 
 
2.17 (0.36 to 4.47) 
 




-1.47 (-4.44 to 1.03) 
0.10 (-1.90 to 1.86) 
-0.22 (-2.42 to 1.74) 
-0.02 (-3.22 to 3.05) 
0.37 (-1.70 to 2.39) 
-0.13 (-2.35 to 1.99) 
 
 
2.35 (0.82 to 4.52) 
 
Assessor and model-

















Model-based difference in bias estimates2 ( )1  
 








Between-trial-pair standard deviation 
 




0.80 (-1.12 to 2.71) 
N/A 
1.10 (-2.47 to 4.61) 
2.62 (0.52 to 4.99) 
1.86 (-0.89 to 4.89) 
 3.94 (1.43 to 6.85) 
 
3.99 (2.21 to 4.95) 
 




3.80 (1.82 to 6.43) 
5.14 (1.79 to 9.52) 
2.59 (0.51 to 5.00) 
4.67 (1.86 to 8.50) 
2.90 (0.76 to 5.56) 
4.32 (1.78 to 7.57) 
 
2.03 (0.41 to 4.49) 
 




3.02 (-0.27 to 7.03) 
2.80 (0.92 to 5.13) 
2.67 (0.58 to 5.37) 
1.10 (-0.84 to 2.89) 
5.07 (2.20 to 9.22) 
 4.76 (2.20 to 8.10) 
 
1.84 (0.37 to 4.20) 
 




-0.59 (-3.00 to 1.51) 
1.11 (-0.45 to 2.76) 
2.04 (0.53 to 3.90) 
1.99 (-0.36 to 4.76) 
1.08 (-0.67 to 2.89) 
 0.94 (-0.91 to 2.90) 
 












Sample size justification 
Choice of sample size of 30 meta-analyses per bias domain was based on considering precision of 
estimation of the proportion of pairs for which model-based and opinion-based orderings of biases 
agree. Overlap between the sets of 30 meta-analyses sampled for different bias domains was expected, 
meaning that the total number of sampled meta-analyses was likely to be less than 120. In a sample of 
90 trial pairs (assuming 25% reduction), the standard error for the proportion of pairs with agreement 
would be less than 0.05 (maximum value 0.049 for an observed proportion of 0.5), assuming a high 
between-assessor correlation of 0.8. In each bias domain sample of 30 trial pairs, the standard error 
would be less than 0.1. 
Model fitting 
All regression models were fitted using MCMC methods within WinBUGS (23). We declared vague 
normal(0,10) priors for unknown regression coefficients and a uniform(0,5) prior for all standard 
deviations.  Results were based on 100,000 iterations following a burn-in period of 10,000 iterations 
which was sufficient to achieve convergence.  Convergence was checked using the Brooks-Gelman-






Example information pack for a trial pair 
 
  
Review details  
Review ID:    736  CD number:   CD005496 
Review title:  Probiotics for prevention of necrotizing enterocolitis in preterm infants 
Participants/populations:   Preterm infants < 37 weeks and/or birth weight < 2500 g. 
Interventions:    Enteral administration of any live microbial supplement (probiotics) at any dose for 
more than seven days compared to placebo or no treatment. 
Meta-Analysis details     Meta-analysis ID:    17134 
Comparison details:  Probiotics vs. Placebo or no treatment 
Experimental intervention:   Probiotics 
Comparator intervention:   Placebo or no treatment 
Outcome:    Severe necrotising enterocolitis (stage II-III) 
  
Instructions:  The two trials laid out below are taken from the same meta-analysis.  Please compare 
these two trials with respect to the magnitude of bias due to inadequacies in sequence generation, 





Trial details  Trial ID:   21227     Trial name:  Samanta  2009 
Methods Prospective randomised double-blind control trial Method of generating 
randomisation sequence: Can't tell Allocation concealment: Can't tell Blinding of 
intervention: Can't tell Blinding of outcome measurement: Can't tell Complete 
follow-up: Yes 
Sample size 61 
Participants Gestational age <32 weeks and VLBW infants (<1500 g) started feed enterally and 
survived beyond 48 h of life Demographic data: Probiotics Group N=91, gestational 
age 30.12 (weeks) (1.63), birth weight 1172 (143) Control Group N=95, gestational 
age 30.14 (weeks) (1.59), birth weight 1210 (143) 
Interventions The probiotic group received a probiotic mixture (Bifidobacteria infantis, 
Bifidobacteria bifidum, Bifidobacteria longum and Lactobacillus acidophilus, each 2.5 
billion CFU) with expressed breast milk twice daily, the dosage being 125 g kg  -1  till 
discharge. The control group was fed with breast milk only. 
Outcomes Feed tolerance in terms of days required to reach full enteral feeding Length of 
hospital stay NEC Sepsis Death due to NEC or sepsis 
Notes Neonatal Care Unit of Medical College and Hospital, Kolkata, India Period of study: 
October 2007 - March 2008 Published: 2009 Source of Funding: not specified in 
paper 
 
Risk of bias table          Trial ID:   21227  Trial name: Samanta  2009 




Quote: "infants were randomly assigned to two groups by random number table sequence" 
(p.129) 
No further information provided. 
Allocation 
concealment? 
Not stated whether allocation was concealed prior to assignment 
Paper states this is a prospective randomised double-blind control trial, but detail not 
provided. 
Blinding? Paper states this is a prospective randomised double-blind control trial, but detail not 
provided. 
Quote: "the probiotic-fortified group received a probiotic mixture…with expressed breast milk 
daily…The control group was fed with breast milk only."  (p.129) 
Not stated whether mothers or personnel were aware of allocation. 




Analysis appears to be based on full numbers of participants 




All 3 primary outcome measures reported (feed tolerance, length of hospital stay, 
morbidities). 
Free of other 
bias? 
Birth weight and gestational age were not significantly different between groups. No other 
statitistically significant demographic or clinical variables between groups. 
Adverse effects not reported 
No sample size calculations reported 






Trial details  Trial ID:   21228   Trial name:  Sari 2010 
Methods Single Center Method of generating randomisation sequence: Sequential numbers 
generated at the computer center of the NICU Allocation concealment: Can't tell 
Blinding of intervention: Can't tell Blinding of outcome measurement: Yes Complete 
follow-up: Yes 
Sample size 63 
Participants Gestational age <33 weeks or birth weight <1500 g Demographic data: Probiotics 
Group N=110, gestational age 29.5 (weeks) (2.4), birth weight 1231 (262) Control 
Group N=111, gestational age 29.7 (weeks) (2.4), birth weight 1278 (282) 
Interventions VLBW infants who survived to start enteral feeding were randomised The study 
group were given L. sporogenes with a dose of 350.000.000 colony forming units 
added to breast milk or formula once a day starting with first feed until discharge. 
The control group were fed without L. sporogenes supplementation. 
Outcomes Death or severe NEC NEC (stage 2, 3, = 2) Death (attributable to NEC, not 
attributable to NEC) Total parental nutrition Intraventricular hemorrhage, grade 3-4, 
Sepsis (culture proven, gram negative, gram positive, fungus) NICU stay Feeding 
(amount, full feeding, intolerance) Weight gain 
Notes Turkey Period of study: October 2008 and June 2009 Published: Unpublished Source 
of Funding: not specified in paper 
 
Risk of bias table          Trial ID:   21228   Trial name: Sari 2010 




Quote: "The infants were randomly assigned to one of two groups prospectively. 
Randomization was performed by using sequential numbers generated at the computer 
center of the NICU" (p.435) 
Allocation 
concealment? 
Quote: "The allocations were contained in opaque, sequentially numbered sealed 
envelopes" (p.435) 
Blinding? Blinding of intervention: 
Quote: "the only personnel who knew of the infants' group assignments were the 
investigators and those in the breast-milk team who were not involved in the care of the 
study infants" (p.435) 
Supplementation given to the experimental group did not alter the appearance of the milk 
or formula.  
Quote: "Fresh suspension of supplements were prepared by personnel in the breast-milk 
team who were not involved in the care of the infant and who followed instructions from 
the sealed envelope" (p.435) 
Blinding of outcome: 
Quote: "Whenever an infant was suspected to have NEC [outcome measure], the infant 
was evaluated by two senior-attending neonatologists who did not know the group 




Attrition and exclusions reported, no apparent imputation  




Primary and secondary outcome measures were reported 




Secondary = culture proven sepsis without NEC, intraventricular hemorrhage, feeding 
intolerance, feeding amount per week, days to reach full enteral feeding, wight gain per 
week. 
Free of other 
bias? 
Clinical and demographic characteristics did not differ between groups, except for: 
Quote: " longer duration of umbilical venous catheterization in the probiotics group" 
(p.436) 
Possible effect of this discussed in discussion 
Inclusion/exclusion criteria reported 
Adverse effects were reported. 
Sample size calculations reported - number needed = 111 infants for each arm. Total 
sample = 110 experimental, 111 control  
Quote: "the required sample size was above the actual numbers attained in our study, 






In which of these two trials would you expect inadequacies in each of the listed 
bias domains to cause greater bias towards overestimation of the effect 
estimate of treatment benefits for the experimental intervention? 
Please consider each bias domain separately.  For each bias domain, your decision should be explicit 
to that particular bias, but the whole risk of bias table may be taken into account (i.e. information 
provided under all other bias domain may influence your decision for any one particular domain).  
Please tick only one verdict option per domain and indicate your level of confidence for each verdict 
on a scale of 1 to 5 (1 being not very confident at all and 5 being very confident). 
 
Meta-analysis outcome:    Severe necrotising enterocolitis (stage II-III)  
 Your verdict on bias 
Tick only one of the three possible options for 
each bias domain (each row) 
Confidence level score 
How confident are you about 
this verdict? 
Enter confidence score 
between 1 and 5 for each bias 
domain, where 1 = not at all 
confident; 5 = very confident. 
Bias domain 
 
(tick only one box per row for 
each domain & overall bias) 
Option 1: 
 








Trial A and Trial B 
are equally 
biased 
Sequence generation      
Allocation concealment     
Blinding       
Incomplete outcome data     
Overall risk of bias for this 
outcome 
    
 
Expert Assessor notes (optional) 
If you would like to add a reason for your decision please add it be 
